Sustained loss of a neoplastic phenotype by brief inactivation of MYC

Meenakshi Jain, Constadina Arvanitis, Kenneth Chu, William Dewey, Edith Leonhardt, Maxine Trinh, Christopher D. Sundberg, J. Michael Bishop, Dean W. Felsher*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

564 Scopus citations


Pharmacological inactivation of oncogenes is being investigated as a possible therapeutic strategy for cancer. One potential drawback is that cessation of such therapy may allow reactivation of the oncogene and tumor regrowth. We used a conditional transgenic mouse model for MYC-induced tumorigenesis to demonstrate that brief inactivation of MYC results in the sustained regression of tumors and the differentiation of osteogenic sarcoma cells into mature osteocytes. Subsequent reactivation of MYC did not restore the cells' malignant properties but instead induced apoptosis. Thus, brief MYC inactivation appears to cause epigenetic changes in tumor cells that render them insensitive to MYC-induced tumorigenesis. These results raise the possibility that transient inactivation of MYC may be an effective therapy for certain cancers.

Original languageEnglish (US)
Pages (from-to)102-104
Number of pages3
Issue number5578
StatePublished - Jul 5 2002

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Sustained loss of a neoplastic phenotype by brief inactivation of MYC'. Together they form a unique fingerprint.

Cite this